Researchers reveal genetic links underlying neuroendocrine pancreatic cancer

February 16, 2017 by Elisabeth Lopez, University of Melbourne
Australian researchers reveal genetic links underlying neuroendocrine pancreatic cancer
Credit: Professor Sean Grimmond

An Australian-led international research effort has revealed that genetic changes normally linked to breast, colon and ovarian cancers could also drive a rare form of pancreatic cancer.

Researchers found as many as one in five with pancreatic neuroendocrine tumours (PanNETs) had a clear predisposition for their cancers, even though they had no of the disease.

The findings, published today in the journal Nature, offer the prospect of one day being able to identify people at risk of these cancers, as well as aggressive forms of the disease, and who might respond to current or new targeted therapies.

The breakthrough is the work of researchers at the University of Melbourne, Garvan Institute of Medical Research, QIMR Berghofer Medical Research Institute, The University of Queensland and the Children's Medical Research Institute, as well as European and US teams.

They carried out whole genome sequencing of tumours from 100 Australian patients recruited through the Australian Pancreatic Cancer Genome Initiative (APGI).

Study co-leader Professor Sean Grimmond, the University of Melbourne's Bertalli Chair of Cancer Medicine, said researchers were surprised to find striking similarities between the genetic drivers of PanNETs and other cancers.

"We found that the MUTYH and BRCA2 gene mutations, normally associated with colon and breast cancers, also appear to play an important role in PanNETs," Professor Grimmond said.

"This raises exciting possibilities for how we treat this disease in the future,"

Study co-leader Dr Nicola Waddell, of QIMR Berghofer, said people without a family history of cancer could still carry a faulty gene that increases their risk of developing this tumour.

"The genetic variants we've identified may help to predict how aggressive each patient's tumour is and what sort of treatment they're likely to benefit from," she said.

"In the future, patients at risk of this rare pancreatic cancer could be identifiable through genetic screening."

PanNETs account for about two per cent of the 3,000 cases of diagnosed in Australia each year.

Amber Johns of the APGI at the Garvan Institute said although patients often have a better prognosis than those with more common pancreatic cancers, this group of tumours is highly unpredictable.

"Doctors currently face the challenge of being unable to tell apart patients who would benefit from early aggressive therapy from those who might be spared harsh treatment for less invasive cancers," Ms Johns said.

She said the study data would be freely available to cancer researchers and clinicians, to build on this work.

Explore further: Pancreatic cancer is four diseases, each with new treatment possibilities

More information: Whole genome landscape of Pancreatic Neuroendocrine Tumours, Nature, nature.com/articles/doi:10.1038/nature21063

Related Stories

Pancreatic cancer is four diseases, each with new treatment possibilities

February 24, 2016
An international team led by Australian researchers has studied the genetics of pancreatic cancer, revealing it is actually four separate diseases, each with different genetic triggers and survival rates, paving the way for ...

Study reveals new genetic mechanism driving breast cancer

January 23, 2017
Researchers at the Wellcome Trust Sanger Institute have discovered 'hotspots' of mutations in breast cancer genomes, where mutations thought to be inactive 'passengers' in the genome have now been shown to possibly drive ...

Genomic sequence reveals new treatment options for pancreatic cancer

February 27, 2015
An international project assisted by researchers from The University of Western Australia has offered new hope to patients with pancreatic cancer.

Potential treatment for a specific kind of pancreatic cancer

September 16, 2013
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric ...

New clues to aggressive breast cancer

November 12, 2013
(Medical Xpress)—Queensland scientists have identified a genetic "switch" which indicates whether a woman's breast cancer will spread.

Gene test could pinpoint patients sensitive to new type of cancer drug

December 22, 2016
Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.